Unique ID issued by UMIN | UMIN000009250 |
---|---|
Receipt number | R000010863 |
Scientific Title | The clinical trial investigating the safety in the treatment of osteonecrosis of the femoral head with a local application of recombinant human bFGF gelatin hydrogel for bone regeneration and preventing the femoral head collapse. |
Date of disclosure of the study information | 2012/11/02 |
Last modified on | 2014/07/23 20:19:37 |
The clinical trial investigating the safety in the treatment of osteonecrosis of the femoral head with a local application of recombinant human bFGF gelatin hydrogel for bone regeneration and preventing the femoral head collapse.
The clinical application of recombinant human bFGF gelatin hydrogel for osteonecrosis of the femoral head.
The clinical trial investigating the safety in the treatment of osteonecrosis of the femoral head with a local application of recombinant human bFGF gelatin hydrogel for bone regeneration and preventing the femoral head collapse.
The clinical application of recombinant human bFGF gelatin hydrogel for osteonecrosis of the femoral head.
Japan |
Osteonecrosis of the femoral head
Orthopedics |
Others
NO
The objective of this study is to evaluate the short-term safety in the treatment of osteonecrosis of the femoral head with a local application of recombinant human bFGF gelatin hydrogel.
Safety
Exploratory
Explanatory
Phase I,II
Presence of adverse events
Periodical assessment of clinical outcomes (VAS pain score, UCLA activity score, Harris Hip Score).
Radiological assessment of the stage of osteonecrosis and the repaired femoral head using MRI.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
The local application of recombinant human bFGF gelatin hydrogel into the femoral head of osteonecrosis.
20 | years-old | <= |
80 | years-old | > |
Male and Female
Patients diagnosed with stage-1 or stage-2 osteonecrosis of the femoral head.
The affected femoral head of osteonecrosis can be considered suitable for the treatment with the local administration of bFGF gelatin hydrogel.
The adequate function of major organs is preserved.
Patients with
Osteonecrosis of the femoral head who had been operated of the affected femoral head.
BMI over 30.
Serious complications including uncontrolled diabetes, serious hypertension, severe heart diseases and severe pulmonary diseases etc.
Malignancies treated within 5 years not including carcinoma in situ and intramucosal carcinoma.
Judged inappropriate with the reason for mental disorder or mental status by the treating physician
Active infection
Under treating diabetic retinopathy including preproliferative diabetic retinopathy and proliferative diabetic retinopathy.
Gelatin allergy
Drug allergy considered not to be suitable with this study.
receiving systemic corticosteroids over 10mg dosage of Prednisolone.
10
1st name | |
Middle name | |
Last name | Haruhiko Akiyama |
Kyoto University Hospital
Department of Orthopedic Surgery
54 Kawahara-cho Shogoin Sakyo-ku Kyoto city
1st name | |
Middle name | |
Last name |
Kyoto University Hospital
Department of Orthopedic Surgery
075-751-3360
Department of Orthopedic Surgery, Kyoto University Hospital
Kyoto University Hospital
Other
NO
2012 | Year | 11 | Month | 02 | Day |
Unpublished
Completed
2012 | Year | 10 | Month | 11 | Day |
2013 | Year | 03 | Month | 01 | Day |
2012 | Year | 11 | Month | 02 | Day |
2014 | Year | 07 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010863
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |